Posted by Michael Wonder on 14 Jun 2023
Oral SMA drug Evrysdi passes reimbursement review
2 June 2023 - The nation’s health insurance review agency said Roche's Evrysdi (risdiplam), an oral treatment for spinal muscular atrophy (SMA), was deemed eligible for reimbursement.
The decision came more than two years after Roche’s application.
